All In Biotech

Drug Trial Radar · NCT04510194

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,323

Actual

Start

Jan 1, 2021

Primary completion

Dec 14, 2022

Study completion Dec 14, 2022

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UnitedHealth Group; Northwestern University; Hennepin County Medical Center, Minneapolis; University of Colorado, Denver; Olive View-UCLA Education & Research Institute
First posted
Aug 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. The purpose of this trial is to conduct a 2x3 factorial randomized trials, which efficiently allows the parallel conduct of three randomized trials to understand whether metformin, ivermectin, or fluvoxamine, is superior to placebo for preventing Covid-19 disease progression in non-hospitalized adults with SARS- CoV-2 infection. 2. To understand if the active treatment arms are superior to placebo in improving viral load, serologic markers associated with Covid-19, and gut microbiome in non-hospitalized adults with SARS-CoV-2 infection. 3. To understand if any of the active treatment arms prevent long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection).

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

  • MetforminDrug

    Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.

  • PlaceboDrug

    placebo; appearance and size are exact matching to the three study drugs.

  • FluvoxamineDrug

    An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14

  • IvermectinDrug

    An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Progression to Severe CovidTime frame: 14 Days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Olive View UCLA Medical Center

    Sylmar, California

  • University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center

    Aurora, Colorado

  • New West Physicians

    Golden, Colorado

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • American Health Network of Indiana

    Greenfield, Indiana

  • Hennepin County Medical Center

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.